F. Randy Vogenberg, PhD, RPh, FASHP

Partner, National Institute of Collaborative Healthcare, and Access Market Intelligence
Principal, Institute for Integrated Healthcare
Greenville, SC

Authored Items

Knowledge Gaps and Value-Based Oncology Coverage Related Findings from the 2012 National Employer Survey

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: Healthcare costs are a continued concern among employers and other purchasers, and extend especially to biologics that are being increasingly scrutinized to demonstrate value over time. A significant cost challenge to employers, these drugs create logistical issues for patients, physicians, pharmacies, and manufacturers owing to their unique approval requirements, dosing, side effects, and distribution methods. The costs of biologics are also hard to track, because they show up in medical as well as pharmacy expenditures.

[ Read More ]

Big Data in Cancer Care: Limitations of Drug Claims

March 2016, Vol 7, No 2 - Employers’ Perspective

As one part of an ongoing macrotheme regarding big data, understanding the benefits and limitations of using drug claims in employer-based population health is an important topic for employers in their health plan coverage strategies. Pharmacy claims are a common source of data used to describe the uses of cancer medications by employees and by their covered family members. Despite the availability of these data and a plethora of analyses, however, several limitations must be considered when interpreting drug use data. [ Read More ]

Telehealth Applications in Patient Care

June 2016, Vol 7, No 5 - Employers’ Perspective

The term telehealth is used interchangeably with telemedicine by some organizations. However, telemedicine is typically associated with the delivery of traditional clinical diagnosis and monitoring by using some form of medical technology, whereas telehealth has a much broader definition that comprises education, disease awareness, and wellness, in addition to the use of technology to connect physicians to patients. [ Read More ]

Drug Costs, and Employers as Purchasers of Care

April 2017, Vol 8, No 2 - Employers’ Perspective

Unlike other countries around the world, the United States does not regulate or negotiate drug prices. In general, the European Union members (eg, United Kingdom, France, Germany), Australia, and other countries incorporate pricing at the time of new drug approval, and allow the use of a new drug when it provides a significant clinical benefit over existing drugs, relative to the drug price. [ Read More ]

Strategic Insights on Midsize Employers and Cancer Care Coverage

April 2019, Vol 10, No 2 - Employers’ Perspective

It is no surprise that healthcare costs are at an all-time high and continue to take center stage in political, social, and economic debates. Employers, as health plan sponsors and as purchasers of care, are looking to take matters into their own hands and tackle the problem through innovative reimbursement strategies. Not all employers, however, are built the same. Experiences in controlling healthcare costs vary between small and large employers. The most affected employers are in the middle and are known as midsize employers. [ Read More ]